Bone morphogenetic protein in spine surgery: Current and future uses

Journal of the American Academy of Orthopaedic Surgeons

Volumn 20, Issue 9, 2012, Pages 547-552

  Even, Jesse ^a   Eskander, Mark ^a   Kang, James ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BONE PROSTHESIS; HUMAN; ILIAC BONE; REVIEW; SPINE FUSION; TRANSPLANTATION;

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; BONE SUBSTITUTES; HUMANS; ILIUM; RECOMBINANT PROTEINS; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867888086     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/JAAOS-20-09-547     Document Type: Article

References (36)

1. Israel DI, Nove J, Kerns KM, Moutsatsos IK, Kaufman RJ: Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 1992;7(2):139-150.
2. Wozney JM, Rosen V: Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 1998;346:26-37. (Pubitemid 28046864)
3. Wozney JM, Rosen V, Celeste AJ, et al: Novel regulators of bone formation: Molecular clones and activities. Science 1988;242(4885):1528-1534. (Pubitemid 19023695)
4. Carragee EJ, Ghanayem AJ, Weiner BK, Rothman DJ, Bono CM: A challenge to integrity in spine publications: Years of living dangerously with the promotion of bone growth factors. Spine J 2011;11(6):463-468.
5. Carragee EJ, Hurwitz EL, Weiner BK: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J 2011;11(6):471-491.
6. Carragee EJ, Hurwitz EL, Weiner BK: Carragee et al respond [in reply to: Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY: Reply to "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned." Spine J 2011;11(11):1082-1083] Spine J 2011;11(11):1083-1086.
7. Carragee EJ, Mitsunaga KA, Hurwitz EL, Scuderi GJ: Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: A cohort controlled study. Spine J 2011;11(6):511-516.
8. Dmitriev AE, Lehman RA Jr, Symes AJ: Bone morphogenetic protein-2 and spinal arthrodesis: The basic science perspective on protein interaction with the nervous system. Spine J 2011;11(6):500-505.
9. Glassman SD, Gum JL, Crawford CH III, Shields CB, Carreon LY: Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear. Spine J 2011;11(6):522-526.
10. Helgeson MD, Lehman RA Jr, Patzkowski JC, Dmitriev AE, Rosner MK, Mack AW: Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion. Spine J 2011;11(6):507-510.
11. Kang JD: Another complication associated with rhBMP-2? Spine J 2011;11(6):517-519.
12. Mirza SK: Folly of FDA-approval studies for bone morphogenetic protein. Spine J 2011;11(6):495-499.
13. Spengler DM: Resetting standards for sponsored research: Do conflicts influence results? Spine J 2011;11(6):492-494.
14. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA: Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002;15(5):337-349.
15. Burkus JK, Sandhu HS, Gornet MF: Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine (Phila Pa 1976) 2006;31(7):775-781.
16. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA: Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2002;27(21):2396- 2408. (Pubitemid 35266228)
17. Ong KL, Villarraga ML, Lau E, Carreon LY, Kurtz SM, Glassman SD: Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 2010;35(19):1794-1800.
18. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA: A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976) 2003;28(12):1219-1224, discussion 1225. (Pubitemid 36734609)
19. Boakye M, Mummaneni PV, Garrett M, Rodts G, Haid R: Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2005;2(5):521-525.
20. Dawson E, Bae HW, Burkus JK, Stambough JL, Glassman SD: Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation: A prospective randomized trial. J Bone Joint Surg Am 2009;91(7):1604-1613.
21. Dimar JR, Glassman SD, Burkus KJ, Carreon LY: Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006;31(22):2534-2539, discussion 2540. (Pubitemid 44632234)
22. Dimar JR II, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY: Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009;91(6):1377-1386.
23. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG: Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006;31(24):2813-2819. (Pubitemid 44772783)
24. Robin BN, Chaput CD, Zeitouni S, Rahm MD, Zerris VA, Sampson HW: Cytokine-mediated inflammatory reaction following posterior cervical decompression and fusion associated with recombinant human bone morphogenetic protein-2: A case study. Spine (Phila Pa 1976) 2010;35(23):E1350-E1354.
25. Rihn JA, Patel R, Makda J, et al: Complications associated with singlelevel transforaminal lumbar interbody fusion. Spine J 2009;9(8):623-629.
26. Sanfilippo JA, Johnson LJ, Rihn JA, Albert TJ, Hilibrand AS: BMP-2 causes increased post-operative radiculitis following TLIF. Presented at the 22nd Annual Meeting of the North American Spine Society, Austin, Texas, October 23-27, 2007.
27. US Food and Drug Administration Orthopaedic and Rehabilitation Devices Advisory Panel: Executive Summary for P050036 Medtronic's AMPLIFY™ rhBMP-2 Matrix. July 27, 2010. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/ UCM220079.pdf. Accessed July 9, 2011.
28. Boden SD, Kang J, Sandhu H, Heller JG: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: A prospective, randomized clinical pilot trial. 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002;27(23):2662-2673. (Pubitemid 35425320)
29. Ahlmann E, Patzakis M, Roidis N, Shepherd L, Holtom P: Comparison of anterior and posterior iliac crest bone grafts in terms of harvest-site morbidity and functional outcomes. J Bone Joint Surg Am 2002;84(5):716-720.
30. Carragee EJ, Bono CM, Scuderi GJ: Pseudomorbidity in iliac crest bone graft harvesting: The rise of rhBMP-2 in short-segment posterior lumbar fusion. Spine J 2009;9(11):873-879.
31. Howard JM, Glassman SD, Carreon LY: Posterior iliac crest pain after posterolateral fusion with or without iliac crest graft harvest. Spine J 2011;11(6):534-537.
32. St John TA, Vaccaro AR, Sah AP, et al: Physical and monetary costs associated with autogenous bone graft harvesting. Am J Orthop (Belle Mead NJ) 2003;32(1):18-23.
33. Kleeff J, Maruyama H, Ishiwata T, et al: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116(5):1202-1216. (Pubitemid 29203031)
34. Laitinen M, Jortikka L, Halttunen T, et al: Measurement of total and local bone morphogenetic protein concentration in bone tumours. Int Orthop 1997;21(3):188-193. (Pubitemid 27371123)
35. Yoshikawa H, Rettig WJ, Lane JM, et al: Immunohistochemical detection of bone morphogenetic proteins in bone and softtissue sarcomas. Cancer 1994;74(3):842-847. (Pubitemid 24237463)
36. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P: Bone morphogenetic proteins and cancer: Review of the literature. Neurosurgery 2010;66(2):233-246.